A Phase IIa, Randomized, Double-blind, Placebo-controlled Study of TQA3526 in the Treatment of Naive or Previously Treated PBC Patients
Latest Information Update: 05 Dec 2022
At a glance
- Drugs TQA 3526 (Primary)
- Indications Primary biliary cirrhosis
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 24 Feb 2020 New trial record